View in EDS HTML Full Text PDF Full Text

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Saved in:

Bibliographic Details
Title:	Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.
Authors:	Quinten, C., Kenis, C., Decoster, L., Debruyne, P. R., De Groof, I., Focan, C., Cornelis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J. C., Baitar, A., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., Specenier, P.
Source:	Quality of Life Research. Mar2019, Vol. 28 Issue 3, p663-676. 14p. 1 Diagram, 4 Charts, 1 Graph.
Subjects:	Quality of life, Cancer chemotherapy, Older patients, Cancer patients, Geriatric Depression Scale, Cytoreductive surgery, Geriatric assessment
Abstract:	Purpose: Using the EORTC Global Health Status (GHS) scale, we aimed to determine minimal clinically important differences (MCID) in health-related quality of life (HRQOL) changes for older cancer patients with a geriatric risk profile, as defined by the geriatric 8 (G8) health screening tool, undergoing treatment. Simultaneously, we assessed baseline patient characteristics prognostic for HRQOL changes.Methods: Our analysis included 1424 (G8 ≤ 14) older patients with cancer scheduled to receive chemotherapy (n = 683) or surgery (n = 741). Anchor-based methods, linking the GHS score to clinical indicators, were used to determine MCID between baseline and follow-up at 3 months. A threshold of 0.2 standard deviation (SD) was used to exclude MCID estimates too small for interpretation. Logistic regressions analysed baseline patient characteristics prognostic for HRQOL changes.Results: The 15-item Geriatric Depression Scale (GDS15), Visual Analogue Scale (VAS) for Fatigue and ECOG Performance Status (PS) were selected as clinical anchors. In the surgery group, MCID estimates for improvement and deterioration were ECOG PS (5, 11), GDS15 (5, 2) and VAS Fatigue (3, 9). In the chemotherapy group, MCID estimates for improvement and deterioration were ECOG PS (8, 7), GDS15 (5, 4) and VAS Fatigue (5, 5). Estimates with were > 0.2 SD threshold. Patients experiencing pain or malnutrition (surgery group) or fatigue (chemotherapy group) at baseline showed a significantly stable or improved HRQOL (p < 0.05) after their treatment.Conclusion: The reported MCID for improvement and deterioration depended on the anchor used and treatment received. The estimates can be used to evaluate significant changes in HRQOL and to determine sample sizes in clinical trials. [ABSTRACT FROM AUTHOR]
	Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection
Full text is not displayed to guests. Login for full access.

Be the first to leave a comment!